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https://doi.org/10.1016/j.celrep.2020.107611SUMMARYThe ribosome is an RNA-protein complex that is essential for translation in all domains of life. The structural
and catalytic core of the ribosome is its ribosomal RNA (rRNA). While mutations in ribosomal protein (RP)
genes are known drivers of oncogenesis, oncogenic rRNA variants have remained elusive. We identify a can-
cer-specific single-nucleotide variation in 18S rRNA at nucleotide 1248.U in up to 45.9%of patients with colo-
rectal carcinoma (CRC) and present across >22 cancer types. This is the site of a unique hyper-modified
base, 1-methyl-3-a-amino-a-carboxyl-propyl pseudouridine (m1acp3J), a >1-billion-years-conserved RNA
modification at the peptidyl decoding site of the ribosome. A subset of CRC tumors we call hypo-
m1acp3J shows sub-stoichiometric m1acp3J modification, unlike normal control tissues. An m1acp3J
knockout model and hypo-m1acp3J patient tumors share a translational signature characterized by highly
abundant ribosomal proteins. Thus, m1acp3J-deficient rRNA forms an uncharacterized class of ‘‘onco-ribo-
some’’ which may serve as a chemotherapeutic target for treating cancer patients.INTRODUCTION
The ribosome is a massive ribonucleoprotein particle (RNP)
responsible for the transformation of genetic information en-
coded as nucleic acids into functional proteins encoded as
amino acids. Unlike most RNPs, it is ribosomal RNA (rRNA)
and not ribosomal proteins (RPs) that form the most ancient
and catalytic core of the complex (Cech, 2000). rRNA is further
functionalized by a constellation of at least 14 distinct chemical
modifications acrossR200 sites (Taoka et al., 2016), clustering
around active sites of the ribosome (Sloan et al., 2017), yet the
function of many rRNA modifications remains unclear.
The human ribosome contains >80 RPs and 4 rRNAs, totaling
80% of cellular RNA. During the initial human genome
sequencing project, ribosomal DNA (rDNA) loci were systemati-
cally excluded from the reference genome (Lander et al., 2001),
given that a reference sequence of the rRNA gene,RNA45S, was
available and the 80–800 rDNA copies were believed to be ho-
mogeneous (Elder and Turner, 1995). However, there was early
evidence for rDNA polymorphism in humans (Kuo et al., 1996;
Leffers and Andersen, 1993). Thus, as technology and
sequencing consortium projects revolutionized genomics and
transcriptomics, our understanding of rDNA variation has
lagged.This is an open access article undrDNA sequence variation at the intra- and inter-individual
levels has been documented in multiple species, including hu-
mans (Bik et al., 2013; Rabanal et al., 2017; Babaian, 2017;
Kim et al., 2018; Parks et al., 2018), but the functional implica-
tions of rDNA variation remain elusive. Mutations of RP genes
and ribosome biogenesis factors can cause a class of diseases
called ribosomopathies, including Diamond Blackfan anemia
(DBA) (Nakhoul et al., 2014), and some cancers (Goudarzi and
Lindstro¨m, 2016). It has been hypothesized that cancer cells
contain a functionally specialized class of ribosomes to facilitate
rapid protein synthesis called the ‘‘onco-ribosomes’’ (Shi and
Barna, 2015; Shi et al., 2017; Dinman, 2016). Cancer genomics
has supported this notion with the identification of several onco-
genic driver mutations in RP genes (Goudarzi and Lindstro¨m,
2016), the best characterized of which are RPL10 (uL16)
p.R98S in T cell acute lymphoblastic leukemia (Girardi et al.,
2018; Kampen et al., 2019) and RPS15 (uS19) C0-terminal muta-
tions in chronic lymphocytic leukemia (Bretones et al., 2018). In
addition, germline mutations such as those in DBA patients
and in RPS20 can lead to heredity cancers, including colorectal
carcinoma (CRC) (Vlachos et al., 2012; Nieminen et al., 2014).
As RP mutations have been implicated in tumorigenesis, we
hypothesized that rRNA variation or mutation is a cancer driver.
To map functional rRNA sequence variation, we consideredCell Reports 31, 107611, May 5, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. The Hypo-m1acp3J Phenotype in Cancer
(A) i, screen for change in the average variant allele frequency (VAF) across 18S and 28S ribosomal RNA (rRNA) in colorectal cancer (CRC) RNA-seq compared to
patient-matched normal epithelium controls (n = 66). Read coverage and quality drops at extreme GC-content (>90%) regions of 28S; these low-coverage
regions were excluded from further analysis. ii, the common human rRNA polymorphism 28S:r.59G>A ranges from 0.05–0.93 (Tukey’s boxplot) DNA allele
frequency (Babaian, 2017) and was expressed comparably in the normal epithelium between VAFs of 0.01–0.86. Neither allele is directionally selected for during
cancer evolution, which is consistent with neutral drift (padj = 1, t = 0.44). iii, 18S:r.1248.U is significantly enriched (padj = 3.81e8, t = 8.33) for the reference U
allele.
(B) The 18S:r.1248.U base normally undergoes enzymatic hyper-modification to 1-methyl-3-a-amino-a-carboxyl-propyl pseudouridine (m1acp3J) in 3 steps;
SNORA13-guided pseudouridylation; EMG1 N1-methylation; and finally 3-amino-carboxyl-propylation by TSR3, which are not downregulated in hypo-m1acp3J
tumors (Figure S1D).
(C) Perturbation of the Watson-Crick face of the modified base results in a distinct nucleotide misincorporation signature by reverse transcriptase in first-strand
cDNA synthesis, which is read out on both the first (+) and second read pair () of sequencing of matched HCT116 whole-genome DNA- and RNA-seq (Cancer
Cell Line Encyclopedia, Ghandi et al., 2019).
(D) Patient 18S:r.1248.m1acp3J hypo-modification is defined as a decrease in VAF by 3 standard deviations (3s) of the matched-normal samples. Hypo-
m1acp3J is not correlated with the loss of other rRNA modifications detectable by RNA-seq.
(E) The hypo-m1acp3J phenotype is replicated in 3 additional independent cohorts of CRC with patient-matched adjacent normal controls, including 2 cohorts
from The Cancer Genome Atlas (TCGA), colorectal adenocarcinoma (COAD) cohort, and rectal adenocarcinoma (READ) cohort.
(F) Hypo-modification of 18S:r.1248.m1acp3J is prevalent but not ubiquitous across the TCGA cancer cohorts (n = 10,078 patients) and largely absent from
patient-matched normal controls (n = 708).
See also Figure S1.
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OPEN ACCESStumorigenesis as a natural experiment in which polymorphic and
mutant rRNA alleles undergo selective evolutionary changes in
frequency within each patient. We identify a surprising 18S
rRNA single-nucleotide alteration at the decoding core of the ri-2 Cell Reports 31, 107611, May 5, 2020bosomal peptidyl (P) site, affecting up to 45.9% of CRC patients,
making this the most frequent ribosomal variant associated with
cancer to date and potentially revolutionizing future chemother-
apeutic strategies against this disease.
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An Unexpected rRNA Variant in Cancer: Sub-
stoichiometric Modification of 18S.1248.m1acp3J
In an initial screen for cancer-driver rRNA variants, we aligned
RNA sequencing (RNA-seq) reads from 66 CRC tumors and pa-
tient-matched adjacent normal tissue to a single-copy reference
rDNA. To test for allelic selection that is inconsistent with neutral
drift, the patient-matched difference in expressed variant allele
frequency (VAF) was measured for deviation from zero for each
position of 18S and 28S (Figure 1A). Non-reference reads at a
single nucleotide deviated from neutrality, 18S:r.1248.U (padj =
3.81e8). In this cohort, the 18S.1248.U reference allele is recur-
rently selected over non-U or 18S.1248V alleles in a striking
44.9% of CRC patients (Figure 1A); in comparison, oncogenic
KRASG12 codon mutation occurs in only 36% of CRC patients
(Tan and Du, 2012).
At the DNA level, the respective nucleotide RNA45S:4908.T is
invariable in humans and CRC (Babaian, 2017; Figure S1B),
and in the mature rRNA, this uridine undergoes hyper-modifica-
tion to 1-methyl-3-a-amino-a-carboxyl-propyl pseudouridine
(m1acp3J) (Figure 1B) (Taoka et al., 2016). The m1acp3J modi-
fication perturbs standard Watson-Crick base pairing during
complementary DNA (cDNA) synthesis by reverse transcriptase
(RT) (Helm andMotorin, 2017), resulting in basemisincorporation
and enzyme stalling, which is read out as a consistent ‘‘modi-
fication signature’’ in RNA-seq (Figure 1C; reviewed in Helm
and Motorin, 2017). Restated, non-reference, or variant reads
at 18S.1248.U correspond to m1acp3J modification and not a
genetic variation. Thus, the increase in the reference U sequence
suggests that the m1acp3J modification is incomplete or
sub-stoichiometric in CRC tumors, which we call the hypo-
m1acp3J phenotype. The 28S.1321.m1A and 28S.4532.m3U
rRNA modifications also cause a ‘‘modification signature’’
in RNA-seq (Helm and Motorin, 2017). These modifications
do not decrease in CRC tumors or matched normal controls,
excluding a non-specific rRNA modification effect (Figure 1D).
The hypo-m1acp3J phenotype is reproducible at comparable
frequencies (27.8%–45.9%) in 3 additional independent patient-
matched CRC cohorts (Figures 1E and F). Analysis of 10,036
cancer patients and 712 normal controls across an additional
31 cancer patient cohorts reveals that hypo-m1acp3J occurs
at a significant frequency across a diverse set of cancers but is
not pan-cancerous (global recurrence: 9.6%, range: 0%–
52.8%) (Figures 1F and S1).
To validate these findings, we designed a simple and rapid
aminocarboxyl propyl reverse transcription (aRT)-PCR assay
for measuring 18S.1248.m1acp3J modification. The aRT-PCR
is reproducible and quantitative (Figure S2). A critical technical
limitation that also applies to RNA-seq is that different RT
enzymes or RT reaction chemistries result in different base mis-
incorporation rates at 18S.1248.m1acp3J (Figure S2D). Thus,
cross-cohort or cross-experimental comparisons should be
made cautiously (Figures S2B–S2D). Batch effects on VAF are
seen within The Cancer Genome Atlas (TCGA) cohorts, yet
hypo-m1acp3J replicates across batches further supports that
hypo-m1acp3J is occurring in tumors specifically (Figures S1C
and S1D).We validated that the hypo-m1acp3J phenomenon also oc-
curs in CRC cell lines assayed as a single batch and confirmed
that the results are not a sequencing artifact (Figure S2E). To
test whetherm1acp3J-deficient rRNA incorporate intomature ri-
bosomes, we isolatedmonosomes and polysomes and detected
low m1acp3J modification levels in mono- and di-somes
(Figure S2F).
As the molecular, biological, and medical significance of
18S.1248.m1acp3J unfolds, it is obvious that genotyping tech-
nologies (e.g., sequencing, our aRT-PCR assay for m1acp3J)
and previous m1acp3J assays (e.g., primer extension) can be
adapted as affordable and rapid diagnostic/prognostic assays.
18S:1248.m1acp3J Is an Ancient Modification at the
Decoding Core of the P Site
We next investigated the evolutionary and structural characteris-
tics of 18S.1248.m1acp3J for functional insight. The 18S:1248.U
base and m1acp3J modification are absolutely conserved
across Eukarya at a residue located in the loop of universal helix
31 (Figures S3A–S3D). TSR3 is the aminocarboxyl propyl trans-
ferase that deposits the acp3 at 18S.1248.U (Meyer et al., 2016),
and it only modifies this single rRNA position in 100% of mature
rRNA molecules in Eukaryotes (Taoka et al., 2018; Yang et al.,
2016).
Structurally, 18S.1248.m1acp3J is solvent exposed at the ri-
bosomal P site, immediately adjacent to the codon:anti-codon
interface (Figure 2). Cryo-EM structures (Li et al., 2019; Natchiar
et al., 2017) and our molecular dynamics (MD) simulations
implicate the m1acp3J modification in a direct interaction
with P site tRNA. The modification carboxyl moiety forms a
hydrogen bond with the universally conserved (Jindal et al.,
2019) RPS16 p.R146 (Figures S3E–S3G), and transfer RNA
(tRNA) interaction is aided by the m1 modification, which stabi-
lizes the base rotation angle (Figures S3H and S3I). Unlike
TSR3, the m1 transferase of 18S.1248, EMG1, is essential,
and its mutation causes Bowen-Conradi syndrome (OMIM:
211180; Armistead et al., 2009; Wurm et al., 2010), supporting
the idea that the modification of 18S.1248 plays a crucial role in
P site function.
Start AUG codon selection and translational initiation are
rate-limiting steps in protein synthesis and both occur at the
P site. Thus, the hypo-m1acp3J phenotype may demarcate
a class of onco-ribosome with deregulated translation. It is
noteworthy that the 2 largest effect-size RP cancer-driver mu-
tations also occur at the ribosomal P site-tRNA interface, the
RPL10 p.R98S at the peptidyl transfer site (Girardi et al.,
2018; Kampen et al., 2019), and the RPS15 C0 tail mutations
adjacent (<12 A˚) to 1248.m1acp3J (Figure 2A), suggesting
that the ribosomal P site is a convergent multi-cancer onco-
genic hotspot.
Since the discovery of streptomycin in 1944, the ribosome
has been the target of several important classes of drugs
(McCoy et al., 2011). The pervasive and recurrent loss of a sol-
vent-exposed and dipole-charged acp3 modification at the de-
coding core of the small subunit (SSU) raises the possibility
that this pocket may be therapeutically exploited with ribo-
some-targeting antibiotics or their derivatives as a next-genera-
tion chemotherapy.Cell Reports 31, 107611, May 5, 2020 3
Figure 2. 18S:1248.m1acp3J Is Located at
the Peptidyl (P) Decoding Site
(A) The mRNA channel of the human small subunit
(SSU) cryoelectron microscopy (cryo-EM) struc-
ture with resolved basemodifications (PDB: 6EK0;
Natchiar et al., 2017). The 18S:1248.m1acp3J
(red) nucleotide is on the loop of the universal helix
31 (see also Figure S3), exposed to the mRNA
channel at the center of the P site. The chronic
lymphocytic leukemia (CLL) driver mutations in the
RPS15 C0 tail (green) are <12.8 A˚ from
18S:1248.m1acp3J. The minimal distance is likely
shorter as the 10 C0-terminal residues of RPS15
that extend into the P site are labile and not
modeled.
(B) Cryo-EM structurewith a peptidyl/exit (P/E) site
tRNA, 18S.1248. J, and 18S.1701.C base stack
with the ribose and base of the tRNA.34.C,
respectively (PDB: 6OLE; Li et al., 2019).
18S.1248.m1acp3J modification contributes to P
site decoding site stability via interaction with P
site tRNA and RPS16.
See also Figures S3E–S3I.
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Ribosomal Protein mRNA Translation
To delineate the function of 18S.1248.m1acp3J, we generated
TSR3 knockout (KO) CRC cell lines (HCT116). Similar to yeast
(Meyer et al., 2016), TSR3 is non-essential and we isolated 2
TSR3 homozygous KOs (TSR3[KO 1,3]), a heterozygous KO
(TSR3[Het 2]) and 3 wild-type (WT) control clones (WT[1–3]).
KOs were functionally confirmed by 5 independent m1acp3J
assays and editing sites validated by RNA-seq, with TSR3
[Het 2] showing an intermediate or hypo-m1acp3J phenotype
(Figures 3A, S2G–S2I, and S4). The hypo-m1acp3J seen in
TSR3[Het 2] is more severe than that seen in CRC cell lines
(Figure S2E), but comparable to what is observed in CRC pa-
tient tumors (Figure S1A). SCARLET shows the presence of
the J and m1J precursor bases at 18S.1248 in TSR3[KO 1]
cells (Figure S2H). This demonstrates that the loss of the
acp3 modification via TSR3[KO] is necessary for RT-mediated
nucleotide misincorporation as measured by RNA-seq, and
further supports the possibility that hypo-m1acp3J tumors
contain sub-stoichiometric loss of the acp3 moiety.
Morphologically, the HCT116 clones were indistinguishable
and showed that comparable rapid growth, cell-cycle
timing, and loss of TSR3 did not alter global protein translation
rates (Figures 3B–3D). To determine how the loss of
18S.1248.m1acp3J modification alters translation, we charac-
terized the transcriptome (RNA-seq) and translatome (ribo-seq)
of these cells and validated our findings by global mass spec-
trometry (Figures S4–S6).
Transcriptionally, gene set enrichment analysis (GSEA)
revealed that TSR3[KO]/[Het] (versus WT) cells were
dominated by a proliferative tumor expression signature,
characterized by Rb-depletion and/or elevated-E2F
transcription factor activity (Figures 3E and S5H; Table S1C).
However, TSR3[KO]/[Het] cells also have a paradoxical
decrease in translation of the same E2F target genes4 Cell Reports 31, 107611, May 5, 2020(Figure S5), stressing the specificity of using RNA-expression
gene-set classifiers.
To determine how the loss of the 18S.1248.m1acp3J modi-
fication alters translation, we contrasted translational efficiency
between genotypes. TSR3[KO]/[Het] cells showed a remark-
able enrichment (versus WT) in the translation of RPs, such
as RPS8 and RPL4, with an associated depletion of RP
mRNA (Figures 3F, S5, and S6), yet overall translation rates
and polysome profiles of TSR3[KO]/[Het] cells were not altered
(Figures 3D and S6E).
To validatewhether this RPmRNA-protein signature is present
in cancer patients, we analyzed the Clinical Proteomic Tumor
Analysis Consortium (CPTAC)-CRC cohort with tumor-matched
RNA-seq and proteomics data (Vasaikar et al., 2019). Similar to
TSR3[KO]/[Het] cell lines, hypo-m1acp3J CRC tumors share
the same E2F/RB oncogenic gene signature and a proteomic in-
crease in RPs relative to normo-m1acp3J CRC tumor controls
(Figures 3G and 3H; Tables S1C–S1E).
There are two hypotheses with which to interpret the hypo-
m1acp3J phenotype. The ‘‘oncogenic driverhypothesis’’ is
that m1acp3J-deficient rRNA arise in tumorigenesis, and their
dysregulated translation confers a selective advantage to the
cancer, likely via high RP output. The recapitulation of the
TSR3[KO]/[Het] multi-omic phenotype in hypo-m1acp3J
CRC patients supports this causal model. The ‘‘passenger
hypothesis’’ is that m1acp3J deficiency arises as a
consequence of hyper-proliferation and high ribosomal
biogenesis. Rapid cellular turnover (often associated with up-
regulated E2F1 activity) in turn results in the incomplete modi-
fication of rRNA. In this model, the consequences of
m1acp3J-deficient rRNA are near-neutral or tolerably detri-
mental to tumor fitness. Nevertheless, hypo-m1acp3J is
a highly recurrent perturbation to the ancient peptidyl-
decoding core and underlies a greater cancer-translational
phenomenon.
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Figure 3. The Translational Signature of
m1acp3J-Deficient Ribosomes
(A) i, aminocarboxyl propyl reverse transcription
(aRT)-PCR assay (see STAR Methods and Figure
S2) and ii, RNA-seq measurement for nucleotide
misincorporation at 18S:1248.m1acp3J in inde-
pendent clones (biological replicates) of the CRC
HCT116 cell line, with human umbilical vein
endothelial cells (HUVEC) as a normal positive
control.
(B) The fold-change growth (mean +/- standard
deviation) of HCT116 clone populations in culture,
normalized to cell number at 24 h.
(C) Cell-cycle timing analysis of log-growth
HCT116 cell genotypes.
(D) Total protein translation rates measured by
puromycin-incorporation assay and flow cy-
tometry quantification reported as the geometric
mean fluorescent intensity (gMFI).
(E) Summary of significant (false discovery rate q
value < 0.05) gene set enrichment analysis (GSEA)
of RNA-seq comparing HCT116 WT[1–3] versus
HCT116 TSR3[KO 1,3/Het 2] clones.
(F) TSR3[KO/Het] cell GSEA shows no change in
ribosomal protein (RP) mRNA abundance, while
RP translational efficiency and total protein in-
crease.
(G and H) Summary of oncogenic signature GSEA
comparing CPTAC CRC tumors with normo-
m1acp3J and hypo-m1acp3J modification (G).
Gene sets common to HCT116 TSR3[KO]/[Het]
and hypo-m1acp3 CPTAC-CRC patients are bold
and (H) a similar increase in RP abundance is
observed.
See also Figures S4–S6 and Tables S1C–S1E.
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Ribosomes are the fulcrum in the central dogma of molecular
biology. Multi-omics studies have repeatedly highlighted the
discordance between mRNA and protein abundance (Liu
et al., 2016; Vogel and Marcotte, 2012), emphasizing the
role of translational variability in physio-normal and patholog-
ical states. Several recent studies have begun to resolve the
ribosome from a uniform assembly into a rich tapestry of func-
tionally heterogeneous complexes making up distinct transla-
tional compartments in the cell (Dinman, 2016; Slavov et al.,
2015; Xue et al., 2015; Shi et al., 2017; Fujii et al., 2018). Spe-cifically, several rRNA modifications
such as pseudouridylation (Ruggero
et al., 2003; Jack et al., 2011; Penzo
et al., 2015; Sbarrato et al., 2016;
McMahon et al., 2019), ribose 20-O-
methylation (Marcel et al., 2013; Krogh
et al., 2016), and C5-methyl cytosine
(Heissenberger et al., 2019) have been
implicated in altering the translational
capacity of cancer cells (reviewed in
Jonkhout et al., 2017; Bastide and Da-
vid, 2018). Together with m1acp3J,
this supports a broader view of rRNAas a central oncogene, perturbed not genetically, but at the
epigenetic modification level.
The variable and sub-stochiometric loss of m1acp3J in cancer
is noteworthy and suggests that a sub-fraction of the ribosomes
of a cancer cell are affected. Furthermore, the loss of 18S.1248
acp3 modification altered the translation of only a subset of
(RP) mRNA. This suggests that the molecular and possibly
tumorigenic function of acp3 modification is mediated within a
distinct class of ribosome, although further research is needed
to resolve this mechanism.
We identify a pervasive and cancer-specific onco-ribosome
marked by the loss of rRNA m1acp3J modification. TheCell Reports 31, 107611, May 5, 2020 5
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tional recurrence and can be explored as a chemotherapeutic
target.
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488 conjugated. Clone 12D10
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DMEM growth media STEMCELL Technologies Cat# 36250
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Deposited Data
HCT116 WT and TSR3[KO] RNA-seq This study SRA: PRJNA602544
HCT116 WT and TSR3[KO] Ribo-seq This study SRA: PRJNA602544
HCT116 WT and TSR3[KO] TMT-MS/MS This study PRIDE: PXD017483
HCT116 assembled transcriptome This study https://crownproject.s3-us-west-2.amazonaws.
com/pub/hct116-gencode_assembly.gtf
Experimental Models
Human HCT116 Cell line. Passage 3 upon receipt. ATCC CCL-247, RRID:CVCL_0291
HCT116 Cancer Cell Line Encyclopedia DNA-seq
and RNA-seq
Ghandi et al., 2019 SRA: PRJNA523380
CRC Patient Cohort I RNA-seq Seshagiri et al., 2012 EGA: EGAD00001000215
CRC Patient Cohort II RNA-seq Lim et al., 2015 SRA: PRJNA218851
The Cancer Genome Atlas Cohorts RNA-seq Cancer Genome Atlas
Research Network
dbGAP: phs000178.v11.p8
CPTAC-CRC Patient Cohort. RNA-seq Vasaikar et al., 2019 dbGAP: phs000892.v6.p1
CPTAC-CRC Patient Cohort. Proteomics Vasaikar et al., 2019 http://linkedomics.org/cptac-colon/
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Human reference genome, GRCh38/hg38 Genome Reference
Consortium
http://hgdownload.soe.ucsc.edu/goldenPath/
hg38/bigZips/analysisSet/hg38.analysisSet.2bit
Human rDNA reference sequence, hgr1 Babaian, 2017 https://crownproject.s3-us-west-2.amazonaws.
com/pub/hgr1.zip
Gencode simple gene annotation v 31 Frankish et al., 2019 ftp://ftp.ebi.ac.uk/pub/databases/gencode/
Gencode_human/release_31/gencode.v31.basic.
annotation.gtf.gz
Human reference proteome. UniProt https://www.uniprot.org/proteomes/UP000005640
CRAPome 1.1 Contaminant repository for
mass spectrometry
Mellacheruvu et al., 2013 https://www.crapome.org/
Oligonucleotides
See Table S2 DNA/RNA Oligonucleotides
Software and Algorithms
samtools v1.8 Li et al., 2009 http://www.htslib.org/doc/samtools.html
bowtie2 v2.3.5.1 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
bcftools v1.9 Danecek et al., 2011 http://www.htslib.org/doc/bcftools.html
tophat v2.0.14 Kim et al., 2013 https://ccb.jhu.edu/software/tophat/manual.shtml
stringtie v2.0 Pertea et al., 2015 https://ccb.jhu.edu/software/stringtie/
imageJ v1.52h Schneider et al., 2012 https://imagej.nih.gov/ij/
STAR v2.5.2b Dobin et al., 2013 https://github.com/alexdobin/STAR
RiboWaltz v1.1.0 Lauria et al., 2018 https://github.com/LabTranslationalArchitectomics/
riboWaltz
DEseq2 Love et al., 2014 https://bioconductor.org/packages/release/bioc/
html/DESeq2.html
R v3.5.1 R Development Core
Team, 2018
https://www.r-project.org/
VMD v1.9.3 Humphrey et al., 1996 https://www.ks.uiuc.edu/Research/vmd/
NAMD v2.1.2 Phillips et al., 2005 https://www.ks.uiuc.edu/Research/namd/
CHARMM 36 Best et al., 2012 https://www.charmm.org/
Proteome Discoverer v2.4 ThermoFisher https://www.thermofisher.com/us/en/home/industrial/
mass-spectrometry/liquid-chromatography-mass-
spectrometry-lc-ms/lc-ms-software/multi-omics-
data-analysis/proteome-discoverer-software.html
Other
Electronic laboratory notebook for study This study https://github.com/ababaian/Crown
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Artem
Babaian (ababaian@bccrc.ca)
Materials Availability
The HCT116 WT[1-3] and TSR3[KO/Het] cell lines are available upon request, without restriction.
Data and Code Availability
The accession number for the sequencing data (polyA RNA-seq, total RNA-seq and Ribo-seq) reported in this paper is is available on
NCBI Short Read Archive SRA:PRJNA602544. The accession number for the proteomics data reported in this study is available at
PRIDE:PXD017483. Electronic laboratory notebook for these experiments and analysis scripts are available at https://github.com/
ababaian/Crown.e2 Cell Reports 31, 107611, May 5, 2020
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Sequencing and proteomics data-sets
A detailed list of sequencing accessions and patient or sample IDs is in Table S1A. Briefly, datasets are Colorectal Carcinoma (CRC)
RNA-seq cohort I (EGA:EGAD00001000215, Seshagiri et al., 2012), CRC cohort II (SRA:PRJNA218851, Lim et al., 2015), CRC cohort
III and IV (TCGA-COAD and TCGA-READ respectively, dbGAP:phs000178.v11.p8, Cancer Genome Atlas Research Network et al.,
2013), and the CRC-CPTAC cohort (dbGAP:phs000892.v6.p1, Vasaikar et al., 2019). All other (TCGA) cancer RNA-seq cohorts
(dbGAP:phs000178.v11.p8, Cancer Genome Atlas Research Network et al., 2013). CRC whole exome data were from cohort III
(TCGA-COAD, dbGAP:phs000178.v11.p8, Cancer Genome Atlas Research Network et al., 2013), and HCT116 RNA-seq and whole
genome sequencing was from the CCLE project (SRA:SRR8615282 and SRA:SRR8639145 respectively, Ghandi et al., 2019). This
studies’ HCT116 TSR3[KO/Het] polyA RNA-seq, total RNA-seq and Ribo-seq are available on SRA:PRJNA602544 and proteomics
on PRIDE:PXD017483.
HCT116 cell culture
The male colorectal carcinoma cell line HCT116 (CCL-247, ATCC, Manassas, VA) was cultured in complete media [DMEM media
(#36250, STEMCELL Technologies, Vancouver, Canada) supplemented with 10% fetal bovine serum (F1051, Invitrogen, Waltham,
MA)].
Cell lines and clonal isolates were tested to be free of mycoplasma contamination by DAPI staining and microscopy and with
LookOut Mycoplasma Detection Kit (MP0035, MilliporeSigma, Burlington, MA) by manufacturer’s protocol.
METHOD DETAILS
Ribosomal sequence alignment and variant allele frequency calculations
RNA-seq libraries used in this study were prepared via poly-A selection to enrich for the5%of mRNA from total RNA. Since rRNA is
80% of cellular RNA it invariably ‘contaminates’ RNA-seq libraries. Typically, poly-(A) RNA-seq libraries contain 3.55% (+/ 0.685,
95% CI, CRC I cohort, n = 66) of total reads aligned to rDNA. Whole genome DNA-seq (WGS) libraries were processed from initial
fastq files. The 876 TCGA-COAD whole exome DNA-seq (WXS) aligned libraries were downloaded and reads mapping to the contig
‘‘chrUn_GL000220v1’’ (which contains a complete RNA45S gene) were extracted with ‘samtools‘ (Li et al., 2009) into fastq files. 415/
438 cancer samples and 413/438 normal samples had rDNA coverage at a total of 15,175x and 17,936x, respectively. A complete list
of library accessions used in this study is available in Table S1A (Cancer Genome Atlas Research Network et al., 2013; Ghandi et al.,
2019; Lim et al., 2015; Seshagiri et al., 2012).
Libraries were aligned to the hgr1 reference rDNA sequence (Babaian, 2017) with bowtie2 (v. 2.3.5.1, command: ‘bowtie2–very-
sensitive-local -x hgr1 1 < read1.fq.gz > 2 < read2.fq.gz > ‘) (Langmead and Salzberg, 2012). For each cohort of libraries, a
genomic variant call format (GVCF) was created with bcftools (v. 1.9, command: ‘bcftools mpileup -f hgr1.fa –max-depth 10000
-A -min-BQ 30 -b < bam.file.list > ‘) (Danecek et al., 2011).
GVCF files were processed in R by custom scripts to calculate variant allele frequency (VAF). VAF is defined as 1 – reference allele
frequency (reference allele depth of coverage / total depth of coverage) (scripts available at https://github.com/ababaian/crown)
The threshold to define hypo-modification of an RNA base (including 18S.1248.m1acp3J) was defined as three standard devia-
tions below average VAF of the normal samples within the same cohort (false discovery rate = 0.00135) when available. Fixed formalin
paraffin embedded (FFPE) libraries in TCGA were negative for 18S.1248.m1acp3J, 28S.1321.m1A and 28S.4532.m3U modification
signatures and excluded from further analysis. In the CPTAC-CRC cohort (normal RNA-seq is unavailable), hypo-m1acp3J and
normo-m1acp3J was defined by the lower (< 25%) and upper (> 75%) quantiles of samples within a batch.
Generating HCT116 TSR3 knockouts
To generate TSR3 knockouts, 105 HCT116 cells were transfected with 10 nmol of one of three TSR3 targeting Alt-R CRISPR-Cas9
ribonucleoproteins or non-targeting controls (Table S1B) by manufacturer’s protocol (1081059, Integrated DNA Technologies (IDT),
Coralville, IA). After 24 h, single cells from each treatment groupwere isolated by limiting dilution and confirmed to be 1 cell per well by
microscopy. Single cell clones were expanded to 5x105 cells at which point half the culture was frozen (culture media + 10%DMSO)
and half were processed for RNA. Putative knockouts were screened by aRT-PCR assay for loss of acp3, wild-type controls were
randomly selected from non-targeting controls. TSR3 knockouts were genotyped by RNA-seq and functional knockout was
confirmed by three independent m1acp3J assays (Figures 3 and S2).
RNA isolation
Cells for RNA extraction were lysed directly in TRIzol reagent (15596-018, Invitrogen), spun 5 min at 12,000 x g to pellet fat and nu-
clear DNA and then frozen at 80C. RNA extraction was carried out by manufacturer’s protocol. RNA quality was assessed via 2%
denaturing RNA agarose gel electrophoresis (heat treated, 95C for 5 min in 1.5x formamide loading buffer (Masek et al., 2005)) and
concentration/purity assessed by spectrophotometer (NanoDrop 2000, ThermoFisher, Waltham, MA). RNA quality for RNA-seq li-
brary preparation had a >9.9 RIN score measured by Bioanalyzer 2100 (Agilent, Santa Clara, CA).Cell Reports 31, 107611, May 5, 2020 e3
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Primer extension was performed with 1 mg of total RNA, incubated with 2 pmol of PE_1248_BLOCK (IDT) primer and 2U of RNase H
(18021-014, Invitrogen) or mock enzyme treatment at 37C for 20 min followed by heat inactivation at 65C for 10 min. SuperScript III
reverse transcriptase (18080044, lot #2042663, Invitrogen) and the fluorophore labeled PE_1248_FAM primer were added for primer
annealing and RT (1h at 50C) as described previously (Schuster and Bertram, 2014). Labeled cDNAs were re-suspended in 1.5x
formamide loading buffer and heated to 95C for 3 min to eliminate secondary structures (Masek et al., 2005). Samples were sepa-
rated on a 2%agarose gel at 114 V for 3h at 4Cor on a 12.5%polyacrylamide gel at 45mA for 2.5h in 1x TBE. After migration, the gel
was visualized with the Typhoon FLA 9500 laser scanner (FAM filter, 50 mm pixel and 450 V unless otherwise noted, GE Healthcare,
Chicago, IL).
Aminocarboxyl propyl Reverse Transcription (aRT)-PCR for 18S.1248.m1acp3J modification
The aminocarboxylpropyl reverse transcription (aRT)-PCR assay for 1248.m1acp3Jmodification was performed with 1 ug of DNase
treated (AM1907, lot #00733051, Invitrogen) RNA after total RNA quality was assessed by denaturing agarose gel electrophoresis
(Masek et al., 2005). RT reaction was carried out with 220 ng RNA with SuperScript III (18080044, lot # 2042663, Invitrogen), Super-
Script IV (18090010, lot #00721480, Invitrogen), UltraScript 2.0 (PB30.31-10, lot #PB130614-01-5, PCR Biosystems, Wayne PA) and
WarmStart RTx (M0380L, lot #0061705, NEB) by each manufacturer’s protocol with minor modifications. aRT reactions were carried
out with a random hexamer primer only (for rRNA), and not poly(T) oligos. cDNAswere diluted five-fold and 1 uLwas used as template
for PCR [25 cycles: 94C for 30 s, 55C for 30 s, 72C for 30 s; 2mMMgCl2; 0.4 mM dNTP; 3.2% DMSO; with 0.2 mMmacp_F1 and
macp_R1 primers (Table S1B)]. 5/30 uL amplicons were digested with HinFI (R0155S, NEB (25C for 5 s, 37C for 90 min, 80C for
20 min). Samples were separated on a 2.25% agarose gel in 1x TBE at 200 V for 45 min at 4C. After migration, the gel was post-
stained in 1x GelRed (41003, Biotium, Fremont CA) for 30 min. Gels were visualized by UV transillumination, captured in gray scale
with a digital camera and pseudo-colored in ImageJ (Schneider et al., 2012) (v 1.52h, Lookup table > Fire) which retains the original
pixel intensity values but highlights band-intensity visualization. Extended protocol is available in the laboratory notebook, https://
github.com/ababaian/Crown.
SCARLET for 18S.1248.m1acp3Jmodification
The validation of 18S.1248.m1acp3Jwas performed by site-specific cleavage and radioactive-labeling followed by ligation-assisted
extraction and thin-layer chromatography (SCARLET) as previously described (Liu et al., 2013) with minor modifications.
Briefly, 1 mg of total RNA from HCT116WT or TSR3[KO] was annealed with 3 pmol of chimera oligo (oligo sequences in Table S1B)
in 2.5 mL 30 mM Tris-HCl pH 7.5, by heating at 95C for 1 min. The sample was incubated at 44C for 1 h in total volume of 5 mL 0.43
T4 PNK buffer (B0201S, NEB) supplemented with 1 U/ml RNase H (H39500, Epicenter, Madison, WI) and 1 U/ml FastAP (EF0651,
Thermo Fisher Scientific), followed by incubation at 75C for 5 min. 1 mL of radioactive labeling buffer (1 3 T4 PNK buffer, 2.5 U/
ml T4 PNK, 4 mCi/ml [g-32P]ATP) was added to the RNA and incubated at 37C for 1 h and then at 75C for 5 min. The mixture was
then annealed with 4 pmol splint oligo and 4 pmol 116-mer DNA oligo by heating at 75C for 3 min followed by addition of 2.9 mL
ligation buffer (1.4 3 PNK buffer, 0.2 mM ATP, 57% DMSO, 5 U/ml T4 DNA ligase) and incubation for 3.5 h at 37C. The ligation
was stopped by adding an equal volume of RNA urea loading buffer (8 M urea, 100 mM EDTA, 0.025% (w/v) bromphenol blue)
and then was digested by incubated with 1 mL RNase T1/A mixture (EN0551, Thermo Fisher Scientific) at 37C for 16 h. The sample
was loaded on 10% denaturing urea-PAGE to isolate the ligation product, which was desalted by ethanol precipitation. The pellet
was resuspended in 9 mL sodium acetate/acetic acid buffer pH 4.6, supplemented with 2mM ZnCl2 and 5 units of nuclease P1, re-
action was incubated) at 37C for 4 h and thenwas spotted on a TLC plate for separation. The result was visualized on a Typhoon FLA
9500 phosphor imager (GE Healthcare).
Biotinylation of 18S.1248.m1acp3J modification
We have exploited reactivity of the m1acp3J base with N-hydroxysuccinimide esters which was initially described in early 1970’s
(Gillam et al., 1968; Schofield et al., 1970; Friedman, 1972). Briefly, 10 mg of total RNA from HCT116 WT or TSR3[KO] in 47 ml of re-
action buffer (100 mM phosphate buffer pH 8.0, 150 mM NaCl, 0.5 M EDTA pH 8.0) were denatured for 5 min at 70C and placed on
ice. After that 1ml of 100mM NHS-dPEG12-biotin (QBD10198-50MG, Sigma Aldrich) in DMSO was added. Reaction was incubated
on ice for 2 h, every 40 min 1 ml of 100 mM of NHS-dPEG12-biotin was added (3 times in total). After treatment RNA was purified with
Zymo-Spin IIC column, resolved on denaturing agarose gel and blotted on Hyperbond N+ (Amersham) membrane. RNA was UV
crosslinked twice with 1200 mJ followed by incubation in blocking solution (phosphate buffered saline [PBS], pH 7.5, 10% SDS,
1 mM EDTA) for 20 min. The membrane was probed with 1:10000 dilution of 1 mg/ml streptavidin-horseradish peroxidase (Pierce)
in blocking solution for 15 min, washed six times in PBS containing decreasing concentrations of SDS (10%, 1%, and 0.1% SDS,
applied twice each) for 5 min and finally the biotin signal was visualized by ECL detection reagent (10 min exposure time).
RNA-seq
RNA-seq library preparation and sequencing was performed by the BC Cancer Genome Sciences Centre, Vancouver, Canada.
Briefly, 75-bp stranded and paired-end poly-(A) RNA-seq libraries were prepared with NEBNext poly(A) mRNA magnetic isolation
module (E7490L, New England BioLabs (NEB), Ipswich, MA), Maxima H minus First Strand cDNA synthesis kit (K1652, Thermo-e4 Cell Reports 31, 107611, May 5, 2020
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parallel but without poly-(A) selection and only 2x PCR cycles (for adaptor ligation). Libraries were sequenced on a HiSeq 2500 (Illu-
mina, San Diego, CA).
Ribo-seq
Ribosome foot printing (ribo-seq) was performed as previously described (Ingolia et al., 2012) with minor modifications. For cell har-
vesting, the culture medium was aspirated, cells were washed twice with ice-cold PBS supplied with 100 mg/ml cycloheximide and
plates were flash-frozen in liquid nitrogen. For cell lysis, the plates were placed on wet ice and 400 ml of mammalian polysome buffer
(MPB) [20 mM Tris-HCl, pH 7.4, 150 mMNaCl, 5 mMMgCl2, with 1 mMDTT and 100 mg/ml cycloheximide, 1% (vol/vol) Triton X-100,
25 U/ml Turbo DNase (AM2238, Invitrogen) was dripped onto the plates. Cells were scraped, the lysate was collected to fresh 1.5 mL
tube, passed ten times through a 26-gauge needle, cleared by centrifugation at 20,000 x g for 10 min, flash-frozen in liquid nitrogen
and stored at80C until further use. For isolation of ribosome-protected RNA fragments, 240 mL of the lysate was digestedwith 6 mL
of RNase I (AM2294, 100 U/ml, Invitrogen) at room temperature with rotation. After 45 min 8 mL of SUPERase-In (20 U/ml, AM2694,
Invitrogen) was added to reaction and passed through MicroSpin S-400 HR columns (27-5140-01, GE Healthcare) equilibrated
with mammalian polysome buffer. RNA was extracted from the flow-through using Trizol LS (10296-010, Invitrogen) followed by
depletion of ribosomal RNA fragments with the RiboZero Kit (MRZH11124, Illumina). Ribosome-protected RNA fragments were
loaded onto denaturing 17% urea-PAGE gel (EC-829, National Diagnostics) and gel area ranging from 27 nt to 30 nt, defined by cor-
responding RNA markers, was cut out. Purified RNA fragments were subjected to library generation using 30 adaptor 4N-RA3, 50
adaptor OR5-4N, RT primer RTP and PCR primers RP1 (forward primer) and RPI1-15 (reverse primers, containing barcodes). Li-
braries were sequenced on a HiSeq 4000 device (Illumina).
Cell cycle and puromycin incorporation assays
HCT116 cells were seeded at 2x105 cells per 6-well plate and allowed to grow until log-phase of growth at50%–75%confluency. To
detachcells, cellswerewashed twicewithPBS,detachedwith0.5mL0.25%trypsinEDTA (07901,STEMCELL) for 5min atRT, followed
by inactivation with 2.5 mL of complete media and cells pelleted at 300 x g for 5 min at 4C. Pellets were washed twice with cold PBS.
For cell cycle analysis, cells were fixed overnight at 4C in 70%EtOH solution. Fixed cells were washed in PBS and resuspended in
500 ul of staining solution [ Propidium Iodide (50 ug/ml), RNase A (0.1 mg/ml), and 0.05% Triton X-100 in PBS], and incubated 30 min
at RT in the dark followed by a wash step. Flow cytometry was performed on a FACScalibur with CellQuest acquisition software (BD
Biosciences) acquiring at least 10,000 cells per sample and analyzed with FlowJo (v 10.0.8). Cell cycle gating was performed on sin-
gle-cells using the automated ‘Watson Model’.
Puromycin-incorporation assay was performed as previously described (Schmidt et al., 2009). Briefly, cells were pulsed with either
complete media only or complete media containing 10 ug/mL Puromycin (73342, STEMCELL) for 10 min in cell incubator. Cells were
washed twice in pre-warmed PBS and chased for 50 min in incubator. Cells were then detached, washed, and fixed in 2% parafor-
maldehyde in PBS for 15 min at RT. Cells were then washed twice in wash solution (5% FBS, and 0.1% Saponin in PBS). 1x105 cells
were stained in 100 ul of 1:100 anti-puromycin antibody (12D10) conjugated to Alexa Flour 488 (MAEBE343-AF488, MilliporeSigma)
in wash solution for 30 min on ice followed by two final washes in wash solution and resuspension in 100 ul PBS for flow cytometry to
acquire at least 5,000 cells per sample. Unstained controls were performed on puromycin treated cells.
Polysome Fractionation
Polysome fractionation was performed as previously described (Floor and Doudna, 2016), with minor modifications. Media was
removed from 100 mm dish with 107 cells and washed with ice-cold ddH2O containing 100 mM CHX. All subsequent steps were
performed chilled at 4C or on ice. After ddH2O aspiration, cells were incubated for 30 min in 450 mL of hypotonic lysis buffer
[0.1x polysome base buffer (PBB), 150 mM KCl, 20 mM Tris-HCl pH 7.4, 15 mMMgCl2 in ddH2O; with 1% Triton X-100 and 1x pro-
tease inhibitor (4693132001, MilliporeSigma). After confirming >95% free nuclei with a hemocytometer, nuclei were pelleted by
centrifugation at 1,800 x g for 5 min. Cytoplasmic fraction was separated from mitochondria by centrifugation at 10,000 x g for
5 min. 300 mL cytoplasmic lysate was layered atop at 7%–45% sucrose gradient (Gradient Master, BioComp, Fredericton, Canada)
in 1x PBB. Gradients were ultra-centrifuged at 221,600 x g for 2 h at 4C (SW-41Ti rotor, 331362, Beckman Coulter, Brea, CA). Gra-
dients were fractionated (Piston Fractionator, BioComp) into 20 3 300 mL fractions with in-line UV-scanning at 254 nm. Fractions
were immediately frozen at 20C for subsequent RNA extraction.
Ribosomal molecular dynamics simulations
All molecular dynamics (MD) simulations were performed as previously described (Girodat et al., 2019). In brief, 80S ribosomemodels
were derived from available human Cryo-EM structures with a resolved 18S.1248.m1acp3J (PDB: 6EKO for E-site tRNA and 6OLE
for A/P and P/E tRNA) (Li et al., 2019; Natchiar et al., 2017).
For simulations lacking completem1acp3Jmodifications, the base was converted to each respective precursor. Each systemwas
protonated with the psfgen package in VMD 1.9.3, and only e-nitrogen for histidine were protonated (Humphrey et al., 1996). Each
system was solvated with a 10A˚ TIP3P water box with a concentration of 7mM MgCl2 and 100mM KCl using the solvate and auto-
ionize packages, respectively (Humphrey et al., 1996). All minimizations and MD simulations were performed with NAMD 2.1.2 usingCell Reports 31, 107611, May 5, 2020 e5
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from (Xu et al., 2016).
Each system underwent a steepest descent minimization of water for 10,000 steps then water and ions for 100,000 steps twice
followed by minimization of nucleic acid and protein for 50,000 steps and finally the whole system for 100,000 steps. After minimi-
zation all systems were equilibrated to 300 and 350 K for 150 ps. Coordinates of the 350 K equilibration in conjunction with velocities
from the 300 K equilibration were used as initial parameters for the MD simulation. Each system was simulated for 20ns. RMSD,
RMSF, dihedral angel, and distance measurements were performed with VMD 1.9.3 (Humphrey et al., 1996).
Tandem Mass Tag labeling and liquid-chromatography and tandem mass spectrometry (TMT LC-MS/MS)
HCT116 [WT] and TSR3[KO/Het] cells were grown to 80% confluence in a 100mmdish, washed in PBS, detached, andwashed twice
in PBS. Cell suspensions were aliquot into technical triplicates and pelleted before snap freezing. One of each HCT116 [WT] and du-
plicates of HCT116 TSR3[KO/Het] clones were processed for LC-MS/MS. Pellets were lysed in 200 mL lysis buffer [4MGuanidine HCl
(G4505-500G, Sigma), 40 mM 2-chloroacetamide (22790, Sigma), 10mM tris(2-carboxyethyl) phosphine (C4706-2G, Sigma), 5 mM
Ethylenediaminetetraacetic acid (AM9260G, Invitrogen), 1x phosSTOP inhibitor (4906845001, Sigma), 1x cOmplete protease inhib-
itor cocktail, EDTA free (4693132001, Sigma), 50 mM HEPES (H3784-100G, Sigma)].
The cells were lysed by bead beating using Lysing Dmatrix tubes (116913100, Cedarlane Laboratories) in a FastPrep 24 instrument
(116005500, MP Biomedical) at 8 M/s for 30 s, resting 90 s, and a second round of bead beating at 8 M/s for 30 s. Supernatant was
transferred into 1.5 mL lo-bind tubes (022363204, Eppendorf) Protein were solubilized and denatured by heating at 95C for 15 min
with shaking at 1000 rpm in a thermomixer (05-400-205, Fisher Scientific).
All experiments used a 1:1 combination of two different types of carboxylate-functionalized beads, both with a hydrophilic surface
(45152105050350 and 65152105050350, Sera-Mag Speed beads, GE Life Sciences).Themagnetic particles are an average diameter
of 1 mm. The beads were stored at 4C at a concentration of 10 mg/mL, and processed with magnetic racks (PR-Z5481,
FisherScientific)
The Sera-Mag SP3 1:1 bead mix was rinsed once with 200 uL HPLC water (270733, Sigma,) and diluted to a final working concen-
tration of 20 mg/mL. To each sample, 200 mg of beadmixture was added andmixed by pipetting to generate a homogeneous solution.
To induce protein binding to the beads, ethanol (34852, Sigma) was added to achieve a final concentration of 50% (v/v). Bead-protein
solutions were mixed to ensure a homogeneous distribution of the beads and incubated for 5 min at 24Cwith 1000 rpm shaking in a
thermomixer. After incubation, tubes were placed on a magnetic rack for 2 min then the supernatant was removed and discarded.
The beads were rinsed three times with 200 mL of freshly prepared 80% ethanol in water, and the supernatant was discarded each
time. Rinsed beads were reconstituted in aqueous buffer (100 mL, 50 mMHEPES pH 8.0) containing a 1:50 (mg:mg) enzyme to protein
amount of trypsin/LysCmix (V5071, Promega). Mixtureswere incubated for 16 h at 37Cwith 1000 rpm shaking in a thermomixer. The
supernatants were recovered using a magnetic rack and transferred to fresh 1.5mL lo-bind Eppendorf tubes.
TandemMass Tag (TMT) labels (5 mg per vial, 90406, Pierce) were reconstituted in 500 mLof HPLC acetonitrile (34851-4L, Sigma)
and frozen at 80C. Prior to labeling, TMT labels were removed from the freezer and allowed to equilibrate at room temperature. A
standard 13 cell line ‘‘supermix’’ digest mix was prepared as described above and included as an internal standard. Labeling was
performed by addition of TMT label in two volumetrically equal steps of to achieve a 2:1 (mg:mg) TMT label to peptide final concen-
tration with 30 min incubation at room temperature for each labeling step. Reactions were quenched by addition of an equal volume
of 1 M glycine (G8898, Sigma) in water. Labeled peptides were concentrated in a SpeedVac centrifuge (781001010234 + RVT400-
115, Labconco) to remove acetonitrile, combined, acidified to a concentration of 1% trifluoroacetic acid (T6508-100mL, Sigma,) and
peptides were purified using a C18 SepPak (WAT054960, Waters). The SepPak was conditioned with 2 mL 0.1% trifluoroacetic acid
in HPLC grade acetonitrile and equilibrated with 2 mL of 0.1% trifluoroacetic acid in HPLC water. The sample was loaded on the
SepPak and rinsed with 3 mL of 0.1% formic acid (, 56302-50ML-F, Sigma) in HPLC water. Peptides were eluted using two 600
uL aliquots of 80% acetonitrile in HPLC water with 0.1% formic acid.
High-pH reversed phase analysis was performed on an Agilent 1100 HPLC system (G1364C, G1315A, G1313A, G1311A). Frac-
tionation was performed on a Kinetix XB C18 column (2.13 150 mm, 1.7 mm core shell, 100 A˚, Phenomenex, 00F-4498-AN). Elution
was performedwith a gradient of mobile phase A (water and 0.1% formic acid) to 7%B (acetonitrile and 0.1% formic acid) over 2min,
to 25% B over 94 min, to 40% over 17 min, with final elution (80% B) and equilibration (5% B) using a further 7 min all at a flow rate of
450 nL/min. Fractions were collected every min across the elution window for a total of 48 fractions, which were concatenated to a
final set of 12 (e.g., 1 + 13 + 25 + 37 = fraction 1). Fractions were dried in a SpeedVac centrifuge and reconstituted in 0.1% formic prior
to MS analysis.
Analysis of TMT labeled peptide fractions was carried out on an Orbitrap Fusion Tribrid MS (IQLAAEGAAPFADBMBCX, Thermo
Scientific). Samples were introduced using an Easy-nLC 1000 system (LC120, Thermo Scientific). Trapping columns were packed
in 100 mm internal diameter, 360 um outer diameter fused silica capillary (1068150023, Molex) to a length of 25 mm with C18 beads
(Reprosil-Pur, Dr. Maisch GmbH, 3 mm particle size, r13.b9.0001). The analytical column was packed with C18 (Reprosil-Pur, Dr.
Maisch, 3 mm particle size) to a length of 15 cm in a 100 mm 100 mm internal diameter, 360 um outer diameter fused silica capillary
with a laser-pulled electrospray tip. Trapping was carried out for a total volume of 10 mL at a pressure of 400 bar. After trapping,
gradient elution of peptides was performed on and heated to 50 C using AgileSLEEVE column ovens (AS1032 + AS1532H, Analytical
Sales & Service). Elution was performed with a gradient of mobile phase A (water and 0.1% formic acid) to 8% B (acetonitrile ande6 Cell Reports 31, 107611, May 5, 2020
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further 7 min at a flow rate of 375 nL/min.
Data acquisition on the Orbitrap Fusion (control software version 3.1.2412.17) was carried out using a data-dependent method in
positive ionmode. Survey scans covering themass range of 400 – 1200were acquired in profilemode at a resolution of 120,000 (atm/
z 200), with quadrupole isolation enabled, an S-Lens RF Level of 60%, amaximum fill time of 120ms, an automatic gain control (AGC)
target value of 4e5, and onemicroscan. ForMS2 scan triggering, monoisotopic precursor selection was enabled for peptides, charge
state filtering was limited to 2 – 4, undetermined charge states were included, and dynamic exclusion of masses selected one time
was enabled for 15 s with a tolerance of 20 ppm. HCD fragmentation with a maximum fill time of 20 ms, quadrupole isolation, an
isolation window of 1.4 m/z, isolation offset off, a fixed collision energy of 40%, injection for all available parallelizable time turned
OFF, and an AGC target value of 1.2e5 was performed. The Orbitrap was used as the detector in normal scan range mode with a
resolution of 50,000 at 200m/z and the first mass was 120 m/z. Centroided data were collected with one microscan. The total allow-
able cycle time was set to 3 s.
QUANTIFICATION AND STATISTICAL ANALYSIS
Transcriptome and translatome alignment, assembly, and differential expression
RNA-seq reads were aligned to hg38 (GRCh38) reference genome with tophat2 (v.2.0.14) (Kim et al., 2013). Individual transcriptome
assemblies for HCT116 [WT 1-3], [KO 1,2] and [Het 2] libraries were generated with stringtie (v 2.0) (Pertea et al., 2015), and then all
merged together with the human gencode basic gene annotation (v. 31) (Frankish et al., 2019) ultimately yielding the hct116_genco-
de.v31 reference gene set.
To generate a single-copy reference transcriptome for ribo-seq analysis of HCT116, isoform-specific quantification of gene
expression was performed on the hct116_gencode.v31 gene set with ‘stringtie -G hct116_gencode.gtf‘. For each gene with non-
zero expression (> 10 unique reads), the one highest expression isoform (average expression from each clone) was chosen as the
reference transcript for that gene.
For ribo-seq alignment, after read adaptor trimming and alignment to hgr1 as above, unmapped reads were aligned against a
containment file containing human tRNA, mtDNA, snoRNA, snRNA and miRNA sequences. Reads remaining unmapped were
then aligned to hg38 and the hct116_transcriptome with STAR aligner (v. 2.5.2b, command: ‘STAR–genomeDir hg38–readFilesIn <
input.fq > –sjdbFileChrStartEnd hg38/sjdbList.out.tab–outFilterMultimapNmax 10–outFilterMismatchNmax 5–outFilterMatchNmin
15–alignSJoverhangMin 5–seedSearchStartLmax 20–outSJfilterOverhangMin 30 8 8 8–quantMode TranscriptomeSAM‘) (Dobin
et al., 2013). Transcriptome aligned Ribo-seq data were analyzed in R (v. 3.5.1) using the riboWaltz package (v. 1.1.0)(Lauria
et al., 2018).
Gene-level expression and total translation was quantified with the DEseq2 (Love et al., 2014) R package using hg38 aligned bam
files and the hct116_gencode.v31 reference gene set. Ribo-seq Gene expression (RPKM) was calculated based only on reads map-
ping in-frame to a gene CDS, measure translating ribosomes. Translational efficiency was calculated per genotype as log2(Ribo-seq
GeneRPKM / RNA-seq GeneRPKM).
Gene expression and translation differenceswere calculated byGene Set Enrichment Analysis (GSEA, v.4.0.0) (Subramanian et al.,
2005) with ‘-permute gene_set -nperm 5000‘ and standard parameters. Transcriptomic GSEAwas performed using theMSigDB (Lib-
erzon et al., 2015) (v 7.0): hallmark, C2 pathways, C3 motif search, and C6 oncogenic signatures gene sets. Translatomic and pro-
teomic GSEA was performed with C5 Gene Ontology (GO) gene set.
All bioinformatic analyses were scripted for reproducibility and are available at https://github.com/ababaian/crown, RNA-seq
and Ribo-seq data can be directly viewed in the UCSC genome browser at https://genome.ucsc.edu/cgi-bin/hgTracks?
hgS_doOtherUser=submit&hgS_otherUserName=Artem+Babaian&hgS_otherUserSessionName=HCT116_TSR3%2dKO.
Puromycin incorporation assay quantification
Puromycin staining intensity correlated with natural variation in cell size (forward scatter signal, FSC), thus the 488nm staining signal
intensity (anti-puromycin) was normalized by cell size (normalized fluorescence = 250 * anti-puromycin / FSC). The geometric mean
florescent intensity (gMFI) and standard deviation for each sample is reported.
Polysome fractionation quantification
For comparative polysome profiles, the total input per gradient was normalized by taking the area under the curve (AUC) from the
beginning of the SSU peak to the end of the last resolved polysome peak and normalizing the are to 100 artificial units. To normalize
for sedimentary variation between gradients, the distance of the SSU, LSU, monosome, 2-, 3-, 4-some peaks across all gradients
were averaged, and a simple linear regression was applied with the ‘ln‘ function in R (v 3.5.1) to regress peaks to a mean distance.
Raw and processed data and analysis scripts are available in the online electronic notebook.
LC-MS/MS data analysis
Peptide detection and protein inference was performed using Proteome Discoverer (v 2.4). Searches were performed using Sequest
HT and the human proteome from Uniprot plus the CRAP-ome (Mellacheruvu et al., 2013). Tryptic cleavages with 2-6 missed cleav-Cell Reports 31, 107611, May 5, 2020 e7
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OPEN ACCESSages and peptide length of 6-144 was used. The precursor mass tolerance was 10 ppm, fragment mass tolerance was 0.05 Da and
monoisotopic masses were used. Only b- and y-type ions were included in the search. Oxidation was allowed as a dynamic modi-
fication and the protein terminus was allowed to have acetylation, Met-loss, or Met-loss+acetylation as dynamic modifications. TMT
reagents (+229.163 Da) were set as static modifications on the peptide terminus and lysine and carbamidomethyl was assigned as a
static modification of cystine. Percolator was used for scoring with an FDR of 0.01, concatenated Target/Decoy Selection, and vali-
dation based on the q-Value. The maximumDelta Cn was 0.05 and the maximum rank was 0. Unique + Razor peptides were used for
quantification. R (v 3.5.1) was used for data analysis. Peptides were filtered for uniqueness and values were median normalized, and
proteins containing at least two unique peptides were included in downstream differential protein expression analysis. The techni-
cally replicated samples were merged (mean) and statistical protein expression analysis was performed in R.
Statistical tests and reporting
Statistical analysis was performed in R (v 3.5.1). Differences in variant allele frequency (VAF) between tumor and normal patient sam-
ples was two-tailed, paired Student’s t test with degrees of freedom one less than reported n. Bonferonni multiple-testing correction
was applied when screening for changes across 18S and 28S nucleotides. Reported central tendencies are means with error bars as
standard deviation and Tukey’s boxplot report data quantiles throughout the paper unless otherwise stated in figure legend. Signif-
icance (*) was defined as p < 0.05 or FDR < 0.05 unless otherwise noted.
Differential gene expression and translation was tested with DEseq2 (Love et al., 2014) with Benjamini-Hochberg multiple testing
correction at an alpha of 0.05. Multi-group comparisons between HCT116 WT[1],[2],[3] and TSR3[KO 1],[KO 3],[Het2] ribo-seq were
performed with one-way ANNOVA, followed by Tukey’s Honestly Significant Difference (HSD) test if indicated. Genotypic differences
between biological triplicates of WT and TSR3[KO] cells were tested with Student’s t test with 2 degrees of freedom and Benjamini-
Hochberg multiple testing correction at an alpha of 0.05 where indicated.e8 Cell Reports 31, 107611, May 5, 2020
